Knowledge hub

Blog

Choose targets with low risk of side effects pinpointed by Ardigen’s ARDitox platform

Discover Our Gene Regulation Platform
Unconventional γδ T cells as allogeneic cellular products in immunotherapies for cancer.
Boost Your Way to Successful Therapy: AI for Drug Discovery Days
Ardigen – New Corporate Identity
Happy Holidays 2021
Prof. Olivera Finn joined Ardigen’s Scientific Board
Ardigen has received funding for the development of the AI-powered Microbiome Platform.
Gut microbiota’s road to clinical utilization. From bathroom to bedside.
Blog

Off-the-Shelf allogeneic cellular immunotherapies for cancer

Dr. Aleksandra Walczak joined Ardigen’s Scientific Board to support the development of AI platforms for the discovery of cell therapies.
Ardigen obtained a Great Place to Work certification
Current and future directions in CAR-T and TCR-T cell therapies against solid tumors
Conformal Prediction in Classification
Ardigen and OncoArendi join forces for research collaboration
Cross validation – a safeguard for machine learning models
Machine Learning on its road to conquer Microbiome Research
Ardigen and ImmuMap announce a research partnership for T-cell receptor discovery